“The most common type of malignant childhood brain cancer has been identified as seven separate conditions each needing a different treatment, new research has revealed.
“A study by Newcastle and Northumbria universities has found that childhood medulloblastoma can be separated into seven different subgroups which all have their own biological and clinical characteristics.”
“Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating vaccines for cancer.
“Under the new licensing agreement, Immunomic will be able to combine LAMP-Vax, itsinvestigational nucleic acid-based immunotherapy platform, with Annia’s CMV immunotherapy platform. Duke University’s John H. Sampson, MD, PhD, and Duane A. Mitchell, MD, PhD, developed this platform, which was later licensed to Annias.”
“Seasonal influenza vaccination resulted in increased risk of immune-related adverse events (AEs) in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors in a small study. However, the risks of the flu itself may still outweigh the risks associated with vaccination.
” ‘Use of immune checkpoint inhibitors is now standard clinical practice for many oncology patients, and these same patients—particularly those with lung cancer—also face increased risk for complications from influenza,’ said Sacha Rothschild, MD, PhD, of University Hospital Basel in Switzerland, in a press release. ‘Although routine influenza vaccination has long been recommended for cancer patients, there are concerns that it might trigger an exaggerated immune response in this subgroup receiving checkpoint inhibitors.’ ”
“Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with glioblastoma, according to the final results of a phase III trial presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting. Patients treated with tumor-treating fields plus temozolomide had a 37% reduced risk of death compared with those randomized to receive temozolomide alone.”
Stephen Western is a dedicated advocate for people dealing with brain cancer. He started this work in February 2013, when his friend was diagnosed with a type of brain tumor known as an astrocytoma. In order to help her, he began to learn all he could about the science of astrocytoma treatment.
Stephen soon realized that many more patients might benefit from his growing knowledge, so he created the website Astrocytoma Options to share this information and update it as new research emerges. He also helps run another site that focuses on the multi-drug “cocktails” often used in brain tumor treatment.
Although Stephen has no formal scientific training, he is able to help patients better understand their treatment options and stay up-to-date on the latest treatment research. To learn more about his work, I interviewed him via email:Continue reading…
“The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. The products are marketed and sold without FDA approval, most commonly on websites and social media platforms.
” ‘Consumers should not use these or similar unproven products because they may be unsafe and could prevent a person from seeking an appropriate and potentially life-saving cancer diagnosis or treatment,’ said Douglas W. Stearn, director of the Office of Enforcement and Import Operations in the FDA’s Office of Regulatory Affairs. ‘We encourage people to remain vigilant whether online or in a store, and avoid purchasing products marketed to treat cancer without any proof they will work. Patients should consult a health care professional about proper prevention, diagnosis and treatment of cancer.’ ”
“Glioblastoma is the most common brain tumor in humans and also one of the most difficult cancers to treat; patients with this type of cancer only survive about one year from time of diagnosis. Researchers at Baylor College of Medicine, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor, Texas Children’s Hospital and Houston Methodist are investigating a new treatment option using modified T cells with anti-tumor properties with the goal of improving outcomes for patients with glioblastoma.
Their research focuses on engineered T cells that target the protein HER 2 expressed in low levels in glioblastoma cells. Results of a Phase 1 study published in the current issue of JAMA Oncology established the safety of these HER 2-specific, chimeric antigen receptor modified T cells (CAR T cells) when infused in to patients in increasing doses and, importantly, results also showed a clinical benefit to patients.”
“Patients with glioblastoma multiforme, a type of brain cancer, who recurred following radiation therapy and Temodal (temozolomide), did not survive longer when treated with the PD-1 inhibitor Opdivo (nivolumab) compared to standard-of-care treatment with Avastin (bevacizumab).
The findings mean that the randomized CheckMate -143 Phase 3 trial (NCT02017717) has failed to meet its primary objective.
” ‘[Glioblastoma multiforme] is a historically difficult disease to treat and conventional treatment options have demonstrated limited responses,’ Fouad Namouni, MD, head of Oncology Development and head of Medical at Bristol-Myers Squibb, said in a news release. ‘We remain steadfast in our pursuit of treatments for diseases with the highest unmet need and continue our work to determine how our immuno-oncology agents can potentially improve outcomes for these patients.’ ”
“Cytomegalovirus (CMV)-targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM), according to a new study published in Clinical Care Research.
“Despite surgical resection, high-dose radiation, and chemotherapy with temozolomide, GBM patients typically survive a median of 15 months. CMV proteins are expressed in more than 90% of GBM. ‘Recent evidence has also demonstrated that CMV-specific T-cell immunity can be generated to recognize and effectively kill autologous GBM tumor cells expressing endogenous levels of the immunodominant pp65 antigen, providing compelling support for the development of CMV-directed immunotherapy for the treatment of GBM,’ stated the researchers, led by Kristen A. Batich, MD, PhD, a researcher in the departments of neurosurgery and pathology at Duke University Medical Center in Durham, North Carolina.”